All corona articles
-
PHE/DH/DWP guidelineCOVID-19 personal protective equipment (PPE)
This revised guidance concerns use of personal protective equipment (PPE) by health and social care workers, in the context of the current COVID-19 pandemic.
-
Information
Key COVID-19 guidance for community pharmacy
The Guidelines for Pharmacy team has produced the following directory of COVID-19 information and guidance for community pharmacy. Included on this page is a collection of key guidance and advice from PSNC, FIP, and NHS, as well as a list of information for specific groups from a range of ...
-
Information
Key COVID-19 guidance for primary care
The Guidelines team has produced the following directory of COVID-19 information and guidance for primary care. Included on this page is a collection of key guidance and advice from PHE and the NHS, as well as a list of information for specific groups from a range of professional bodies. ...
-
NHS guideline
PHE maintaining immunisation programmes during COVID-19 guideline
A brief summary providing the key points for primary care on maintaining immunisation programmes during the COVID-19 pandemic.
-
NHS guideline
NHS video consulting guideline
This Guidelines summary covers guidance for safe video consulting in general practice. It includes key principles, general information, and recommendations on conducting safe video consultations. Refer to the full guideline for information on: information governance communication with colleagues medico-legal information ...
-
Independent professional body guideline
PCWHF HRT provision during COVID-19 guidance
This summary is intended to aid primary healthcare practitioners in initiating, reviewing, and prescribing hormone replacement therapy for women during COVID-19.
-
NHS guideline
General practice in the context of coronavirus (COVID-19)
This Guidelines summary outlines standard operating procedures for general practices in the context of COVID-19.
-
NHS guideline
NHS guidance on NSAIDs in COVID-19
This summary sets out the clinical policy for the acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19.
-
PHE/DH/DWP guideline
PHE guideline on management of exposure to COVID-19
This summary provides guidance on the management of staff and patients in health and social care settings according to exposures, symptoms, and test results.
-
NICE guideline
COVID-19 rapid guideline: delivery of systemic anticancer treatments
This guideline aims to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic
-
NHS guideline
NHS England COVID-19 community pharmacy guideline
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. This guidance is correct at the time of publishing. The Guidelines team review the information daily and update as ...
-
NICE guideline
COVID-19 rapid guideline: children and young people who are immunocompromised
The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.
-
NICE guideline
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources
-
NICE guideline
COVID-19 rapid guideline: dialysis service delivery
This Guidelines summary covers the provision of care for patients requiring dialysis in the context of the COVID-19 outbreak
-
NICE guideline
COVID-19 rapid guideline: chronic kidney disease
This COVID-19 rapid guideline aims to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.
-
NICE guideline
COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
-
NICE guideline
COVID-19 rapid guideline: managing COVID-19 symptoms in the community
The purpose of this guideline is to provide recommendations for managing COVID‑19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection
-
NICE guideline
COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
-
NICE guideline
COVID-19 rapid guideline: pneumonia in adults
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic.
-
NICE guideline
COVID-19 rapid guideline: cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic. ...
